

# Zoledronic Acid Treatment in Patients With Congenital Dyserythropoietic Anemia

NCT07471516

---

Status	RECRUITING
Phase	Phase 1, Phase 2
Sponsor	Institute of Hematology & Blood Diseases Hospital, China
Enrollment	2 participants

## Key Eligibility Criteria

---

### Inclusion (8)

- Age ≥ 18 years, regardless of gender.
- Diagnosis of Congenital Dyserythropoietic Anemia (CDA) based on clinical presentation, laboratory tests, and family investigation, with the presence of RBM28 mutation and/or increased vacuolization within nucleated red blood cells under light microscopy of bone marrow.
- Presence of anemia (Hemoglobin < 100 g/L at screening) or transfusion dependence (defined as an average transfusion interval of < 8 weeks within the past 3 months).
- Performance status is acceptable (ECOG score 0-2).
- Normal renal function (estimated glomerular filtration rate, eGFR ≥ 60 mL/min/1.73m<sup>2</sup>).
- ... and 3 more (see full listing online)

### Exclusion (7)

- Known hypersensitivity to bisphosphonates or any of their excipients.
- Severe periodontal disease or a recent history (within 6 months) of osteonecrosis of the jaw.
- Hypocalcemia.
- Pregnant or lactating women.
- Currently receiving other experimental drug treatments that may affect erythropoiesis (e.g., Luspatercept).
- ... and 2 more (see full listing online)

## Locations (1 total)

---

Institute of Hematology & Blood Diseases Hospital, Tianjin, China